TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of patients reporting no pain at 16 and 24 hours
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: patient and relative satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety levels post-radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of corticosterone, interleukin‐1beta, TSH and cAMP/cGMP ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum levels of cortisol, ACTH, cGMP and FT4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: N-acetylaspartate (NAA) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Creatine (Cre) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myo-inositol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain experienced when pressure applied to cervical zygapophysial joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinesialgia induced by segmental function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CDAI-70 response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombin Time (TT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: self-reported exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CASI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom-based score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: growth at the age of 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of LC15-0444
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in spherical aberration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decayed and filled surfaces in permanent molars (DFS index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Incidence of decayed, missing and filled surfaces (DMFS index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: attenuation of cutaneous heat pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average milk δ13 C values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of first stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global vascular risk reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients achieving LDL-C < 100 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Further diagnostic procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effectiveness in treating bipolar and unipolar depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity score of ulcerative colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of oral yeast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of Staphylococcus aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of aerobic and facultative gram‐negative bacilli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Substance and relationship outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bone Mineral Density (BMD) at spine and hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Markers of bone turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Healthy infants delivered at term
Endpoint domain: Mortality/survival
Primary endpoint: Overall bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Risk of hospitalisation for somatic acquired disease
Endpoint domain: Adverse events/effects
Primary endpoint: Pressure Pain Threshold (PPT) in CMC joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pressure Pain Threshold (PPT) in scaphoid bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of COX‐1+ NP cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of IL‐5+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement of xerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement of quality of life index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Erosion and joint space narrowing scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: daily salt intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: salt sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CV mortality/HF hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: TOF ratio recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per full responder
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incremental cost per extra full responder
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost-effectiveness of MAL-PDT
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ctrough levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of pain on movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage decrease in urinary protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 12-month angiographic restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Frequency of heavy drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of behavioral troubles
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of hearing damages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rehospitalization for HF
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effective rate of hair removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative morbidity within the first 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Median overall costs during the 3 months follow-up
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: T-cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: No local reaction after third dose
Endpoint domain: Adverse events/effects
Primary endpoint: Post immunization diphtheria antitoxin GMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum level of soluble E‐cadherin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to recurrent positive BS
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in peak pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pressure-time integrals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort level of running shoes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean felodipine area under the plasma concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma peak drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dehydrofelodipine/felodipine AUC ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of severe hypoglycaemic episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Bishop's score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical ripening time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxytocin augmentation requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global left ventricular ejection fraction (LVEF) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intention to treat eradication of H. pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AAdSS mean difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ARTSS mean difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall RQLQ score mean difference
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: self-stigma reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: secrecy reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration of erection leading to successful intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year durable complete response rate
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity and specificity of 13C‐UBT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score of zero
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delta VAS following treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of IgM, IgA, IgG1, and IgG4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentrations of complement components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Noradrenaline concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hsCRP serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: endothelin-1 serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone resorption reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Twelve-week mortality for S. aureus bloodstream infections
Endpoint domain: Mortality/survival
Primary endpoint: Twelve-week mortality for non-bloodstream S. aureus infections
Endpoint domain: Mortality/survival
Primary endpoint: Mean inpatient costs for S. aureus infections
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Annual incidence of any bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Annual incidence of major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: knee pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: BML global score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: BV persistence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Decrease in CNV height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: histologically confirmed complete tumor resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: sleep and daytime functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: adverse events incidence
Endpoint domain: Adverse events/effects
Primary endpoint: sC concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean volume of colloid required until end of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraoperative fluid balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of adverse events up to postoperative day 28
Endpoint domain: Adverse events/effects
Primary endpoint: Reliability of metatarsal head location mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Higher resident satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: decrease in cyst size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in tenderness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in cyst number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication adherence (MPR <0.80)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined clinical endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement at Week 4 and Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of bifid VEP configuration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Establishment of B. canis infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative left ventricular ejection fraction (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of postoperative AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Apparent oral clearance (CLO) of (S)-propafenone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Apparent oral clearance (CLO) of (R)-propafenone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in QRS duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: μ‐Opioid receptor availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dopamine‐regulated habituation of the BR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shift downwards of 1 grade of the haemorrhoidal scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stop bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain ceased
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival free of all-cause hospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: time to severe relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first consumption of any ethanol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: obsessive compulsive drinking scale‐German version (OCDS‐G)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: blood loss during orthognathic operations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: length of triage stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bayley's MDI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PDI index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: latencies of FVEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean comfort ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PASI reduction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in amygdalar size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in hippocampal size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total average physical activity times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete cure of incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective improvement reported by patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Skin temperature increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global sensitivity and pain perception thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy in estimating portion sizes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac events at 5-year follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Implant failure and/or nonunion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blood transfusions
Endpoint domain: Adverse events/effects
Primary endpoint: Disappearance of hyperplastic polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic findings of inflammation and activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum gastrin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Index of Independence in the Activities of Daily Living (ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Jugular cross-sectional areas (CSAs) during head rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of febrile seizures
Endpoint domain: Adverse events/effects
Primary endpoint: Body temperature during febrile episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Greater vital force ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Better self-rated quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Lesser fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: premenstrual symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom cyclicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of nosocomial infection
Endpoint domain: Adverse events/effects
Primary endpoint: Prolongation of absolute latencies of wave I, III, V, and wave I‐III interpeak latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: anti-IIa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heparin clotting assay results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of small-for-gestational age infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Delivery by cesarean section due to non-reassuring fetal status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: bone-to-bone healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: full-thickness tear of the subscapularis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean total case duration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Absolute Nonzero Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNA stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: oxidatively damaged purines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: excretion of 8-oxo-7,8-dihydro-2'-deoxyguanosine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: consumption of fentanyl and midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum retinol values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of dhfr point mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of mdr1 86 resistance allele
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of intraoperative hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aortic and systemic arterial stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: duration of ventilation support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum endotoxin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visual Field Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Pulsatile Ocular Blood Flow (POBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes